ID
22738
Description
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus
Keywords
Versions (1)
- 6/11/17 6/11/17 -
Copyright Holder
Genentech, Inc.
Uploaded on
June 11, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
PHYSICAL EXAM (MONTH 12) CRFs Roche FVF4168G Macular Edema NCT00473330
PHYSICAL EXAM (MONTH 12) CRFs Roche FVF4168G Macular Edema NCT00473330
Description
PHYSICAL EXAM (MONTH 12)
Description
Record any new or worsened findings / conditions on the appropriate Adverse Event CRF.
Data type
boolean
Alias
- UMLS CUI [1]
- C0031809
Description
PHYS_EXAM_DT [PEDT]
Data type
date
Measurement units
- DD/MMM/YY
Alias
- UMLS CUI [1,1]
- C0031809
- UMLS CUI [1,2]
- C0011008
Similar models
PHYSICAL EXAM (MONTH 12) CRFs Roche FVF4168G Macular Edema NCT00473330
C2986440 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])